日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Polymerase Ѳ inhibitors combinations with approved and investigational agents in patient-derived tumor multi-cell type (mct) spheroids.

聚合酶 Ѳ 抑制剂与已批准和正在研究的药物在患者来源的肿瘤多细胞类型 (mct) 球体中的组合

Teicher Beverly A, Dexheimer Thomas S, Chen Li, Silvers Thomas, Jones Eric M, Coussens Nathan P, Eder J Paul, Doroshow James H

Identifying Molecular Properties of Ataxin-2 Inhibitors for Spinocerebellar Ataxia Type 2 Utilizing High-Throughput Screening and Machine Learning

利用高通量筛选和机器学习鉴定脊髓小脑性共济失调2型中Ataxin-2抑制剂的分子特性

Sahay, Smita; Wen, Jingran; Scoles, Daniel R; Simeonov, Anton; Dexheimer, Thomas S; Jadhav, Ajit; Kales, Stephen C; Sun, Hongmao; Pulst, Stefan M; Facelli, Julio C; Jones, David E

RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

RAS通路抑制剂与靶向药物联合使用对多种癌症类型中携带致癌KRAS变异的患者来源球体具有活性

Davoudi, Zahra; Dexheimer, Thomas S; Coussens, Nathan P; Silvers, Thomas; Fox, Raymond G; Kemp, Samantha B; Juneja, Poorva; Morris, Joel; Hollingshead, Melinda G; Takebe, Naoko; Doroshow, James H; Teicher, Beverly A

High-throughput combination screening of Pidnarulex and other G-quadruplex ligands in multi-cell type tumor spheroids

在多细胞类型肿瘤球体中对 Pidnarulex 和其他 G-四链体配体进行高通量组合筛选

Dexheimer, Thomas S; Coussens, Nathan P; Silvers, Thomas; Juneja, Poorva; Jones, Eric; Gore, Steven D; Kunkel, Mark W; Doroshow, James H; Teicher, Beverly A

Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids.

在多细胞类型肿瘤球体中,对靶向药物与 PI3K 抑制剂 inavolisib、alpelisib、duvelisib 和 copanlisib 进行组合筛选

Dexheimer Thomas S, Davoudi Zahra, Coussens Nathan P, Silvers Thomas, Morris Joel, Takebe Naoko, Said Rabih, Moscow Jeffrey A, Doroshow James H, Teicher Beverly A

RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived tumor cell line spheroids

RNA加工激酶抑制剂和表观遗传抑制剂与肿瘤药物或研究性药物联合用于多细胞类型患者来源的肿瘤细胞系球体

Teicher, Beverly A; Dexheimer, Thomas S; Silvers, Thomas; Coussens, Nathan P; Jones, Eric; Gore, Steven D; Kunkel, Mark; Doroshow, James H

Targeted therapy combinations with ipatasertib in multi-cell type 3D tumor spheroid models

在多细胞类型 3D 肿瘤球体模型中,靶向治疗联合 ipatasertib 的疗效

Teicher, Beverly A; Takebe, Naoko; Dexheimer, Thomas S; Silvers, Thomas E; Coussens, Nathan P; Hollingshead, Melinda G; Doroshow, James H

RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived tumor cell line spheroids.

RNA 加工激酶抑制剂和表观遗传抑制剂与肿瘤药物或研究性药物联合用于多细胞类型患者来源的肿瘤细胞系球体

Teicher Beverly A, Dexheimer Thomas S, Silvers Thomas, Coussens Nathan P, Jones Eric, Gore Steven D, Kunkel Mark, Doroshow James H

Combination screen in multi-cell type tumor spheroids reveals interaction between aryl hydrocarbon receptor antagonists and E1 ubiquitin-activating enzyme inhibitor.

在多细胞类型肿瘤球体中进行的组合筛选揭示了芳烃受体拮抗剂与 E1 泛素激活酶抑制剂之间的相互作用

Dexheimer Thomas S, Coussens Nathan P, Silvers Thomas, Jones Eric M, Chen Li, Fang Jianwen, Morris Joel, Moscow Jeffrey A, Doroshow James H, Teicher Beverly A

Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems-based Resource

NCI-60中的靶向研究性肿瘤药物:基于表型系统的资源

Morris, Joel; Kunkel, Mark W; White, Stephen L; Wishka, Donn G; Lopez, Omar D; Bowles, Lori; Sellers Brady, Penny; Ramsey, Patricia; Grams, Julie; Rohrer, Tiffany; Martin, Karen; Dexheimer, Thomas S; Coussens, Nathan P; Evans, David; Risbood, Prabhakar; Sonkin, Dmitriy; Williams, John D; Polley, Eric C; Collins, Jerry M; Doroshow, James H; Teicher, Beverly A